NASDAQ: QURE · Life Sciences · 6 alerts · CIK 1590560
Share price
$21.88Close, Nov 16
Market cap
$1.53B
Shares outstanding
70.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All uniQure N.V. filings on SEC EDGAR ↗
uniQure is transitioning to a commercial-stage entity with FDA priority review for AMT-130, backed by a strong $768.4 million cash position and significant slowing of Huntington's disease progression.
For the nine months ended September 30, 2026, uniQure N.V. reported a net loss of $195.8 million, an increase from the $161.9 million loss in the prior year period. Total assets grew to $940.6 million, supported by a follow-on public offering and the exercise of pre-funded warrants which contributed to a significant increase in additional paid-in capital.
uniQure reported Q3 2026 financial results, highlighting a cash position of $768.4 million which is expected to fund operations into 2030. The company also announced that the FDA has granted Priority Review for its BLA for AMT-130 in Huntington’s disease with a PDUFA date of May 1, 2027.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease. We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
Matthew Kapusta, chief executive officer at uniQure
“As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.”
Matthew Kapusta, chief executive officer at uniQure
uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
uniQure N.V. released a clinical program update for AMT-130 (ifezuntirgene inilparvovec), its gene therapy candidate for Huntington’s disease. The update includes long-term data from ongoing Phase I/II clinical trials and details regarding the enrollment of a fourth cohort. The company is also evaluating neurofilament light chain (NfL) in cerebrospinal fluid as a potential biomarker for disease severity.